Background. We measured the effect of two weight adjusted i.v. doses (0.2 mg per 70 kg and 0.4 mg per 70 kg) of the potent opioid buprenorphine on analgesia and respiratory depression in healthy volunteers. The aim of the study was to compare buprenorphine's behaviour with respect to the occurrence of ceiling (or apparent maximum) in these typical m-opioid protein-(MOP) receptor effects.
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Buprenorphine is a semi-synthetic opioid in clinical use for treatment of acute and chronic pain since 1979. 1 It is a potent analgesic with agonistic activity at the MOP -receptor and antagonistic properties at the KOP-receptor. 2 Human studies show that buprenorphine behaviour is typical of MOP-receptor agonists, with respect to its intended effect (potent and long-lasting analgesia) and side-effects (e.g. it causes sedation, nausea, delayed gastric emptying and respiratory depression). 2 3 In a previous study, in a group of healthy volunteers buprenorphine-induced respiratory depression demonstrated ceiling (or an apparent maximum effect) at doses >0.1 mg per 70 kg. 4 Ventilation at a fixed end-tidal PCO 2 reached maximum peak depression of about 50% of baseline. Buprenorphine's behaviour contrasts that of fentanyl, which showed irregular breathing and apnea at high dose (>100 mg). These findings suggest a greater margin of safety for buprenorphine relative to other potent opioids frequently used to treat severe acute and chronic pain.
However, buprenorphine's safety profile must be considered against the background of its analgesic profile. For example, if the ceiling in respiratory depression coincides with the ceiling in analgesia then the value of buprenorphine would be limited in clinical practice. Recently we observed in rats the occurrence of ceiling in buprenorphine's respiratory effect while no ceiling was observed in buprenorphine's antinociceptive behaviour. 4 5 There are no good experimental human studies available on buprenorphine's analgesic behaviour at doses causing ceiling in respiratory effect. To address this important issue we assessed the effect of two doses of i.v. buprenorphine (0.2 and 0.4 mg per 70 kg) on respiration and analgesia in a group of young and healthy volunteers. Previous studies indicate that 0.2 and 0.4 mg of buprenorphine have similar and limited respiratory effects. 4 
Methods
Twenty volunteers (10 male; aged 22-35 yr, weight 62-92 kg) participated in the study after approval was obtained from the human ethics committee. All subjects were healthy and did not have a history of illicit substance abuse or smoking. They were asked to refrain from stimulants and depressant substances for at least 12 h before the study. Each subject participated once. After arrival in the laboratory the subjects were familiarized with the pain test and breathing apparatus for about 60 min.
Half of the subject group (n=10, 5 male) received a weight adjusted dose of 0.2 mg per 70 kg buprenorphine i.v., the other half a weight adjusted dose of 0.4 mg per 70 kg. The buprenorphine (Reckitt Benckiser Healthcare Ltd, Hull, UK) was infused slowly over 90 s.
Respiration
To study ventilation we used the dynamic end-tidal forcing technique. 6 This technique enables us to force end-tidal PCO 2 (PE to 7 and 14.5 kPa, respectively, throughout the studies. The subjects were comfortably positioned in a hospital bed and breathed through a face mask, positioned over nose and mouth (a nose clip was not used). The face mask received fresh gas (45 litre min À1 ) from a gas mixing system consisting of three mass flow controllers (Bronkhorst High Tec, Veenendaal, The Netherlands) for oxygen, carbon dioxide and nitrogen. A personal computer provided control signals to the mass flow controllers allowing the adjustment of the inspired gas concentrations to obtain the desired end-tidal concentrations. The inspired and expired gas flows were measured at the mouth using a pneumotachograph connected to a pressure transducer (Hans Rudolf, Myandotta, MI, USA) and electronically integrated to yield a volume signal. The volume signal was calibrated with a motordriven piston pump. The oxygen and carbon dioxide concentrations were measured using a gas monitor ( ) were available for on-line analysis (and stored on breath-to-breath basis for further analysis).
Respiration was measured 30 min before the drug was infused (t=À30 min) and at times t=15, 75, 140, 180, 240, 300, 360, 420 and 480 min after the infusion of buprenorphine. Respiratory studies were performed after ventilation at a fixed PE 0 CO 2 of 7 kPa had reached a steady-state. The mean value of 10 consecutive breaths was calculated and used in the data analysis. The ventilatory frequency was recorded and the minute ventilation calculated. Generally no more than 7 min were needed before a measurement at steady-state was obtained. In between respiratory measurements the subjects had the mask removed and analgesia testing was performed.
Analgesia
Acute pain was induced by an electrical current through two surface electrodes (Red Dot, 3M, London, Ontario, Canada) placed on the skin overlaying the tibial bone (shin bone) of the left leg. 7 The electrodes were attached to a computer interfaced current stimulator (CICS, Leiden University Medical Center). The intensity of the noxious stimulation was increased from 0 mA in steps of 0.5 mA per 1 s. The stimulus train consisted of a square-wave pulse of 0.2 ms duration applied at 10 Hz and had a cutoff at 128 mA. The subjects were instructed to press a button on a control panel when no further increase in stimulus intensity was acceptable (pain tolerance). Upon pressing the pain tolerance button, the stimulus train ended. This procedure was performed three times before drug infusion and the mean used as the baseline value (and at t=5, 10, 45, 80, 110, 130, 165, 210, 270, 330, 390, 450 and 490 min after the drug infusion). The current at which pain tolerance occurred was automatically collected and stored on the hard disk of a computer for further analysis. The involvement of the observers in the pain assessments was restricted to training the subjects and to the initiation of the stimulus train during the studies.
Data analysis
Data analysis was performed on the absolute respiration and pain tolerance values and on the values relative to baseline (i.e. the change in minute ventilation and the change in pain tolerance). Data are reported as mean (SD). Statistical analysis was performed using SigmaStat 3.1 (Systat Software, Inc., Point Richmond, CA, USA). A two-way, repeated measures ANOVA was applied to detect a significant difference of buprenorphine dose on respiration or analgesia and to detect whether sex differences were present.
Post-hoc analysis was by t-test. P-values <0.05 were considered significant.
Results
All subjects completed the study without major side-effects. Most prominent side-effects were nausea and vomiting which occurred in 80 and 40% of subjects, respectively. Nausea/vomiting remained untreated throughout the study period.
Respiration
The two buprenorphine doses had a similar effect on ventilation. Baseline ventilation at a PE 0 CO 2 of 7 kPa did not differ between the two dose groups: 24.2 (SD 2.3) litre min À1 in the 0.2 mg vs 23.5 (1.9) litre min À1 in the buprenorphine 0.4 mg group. After infusion of the drug ventilation showed a rapid decline and reached peak depression between t=150 and 180 min (Fig. 1 ). This effect was dose-independent with respect to timing and magnitude. At peak respiratory depression: minute ventilation was 13.1 (1. At buprenorphine 0.2 mg a small short-lived analgesic effect was observed with a maximum increase in pain tolerance current of 6.7 (2.8) mA occurring at t=75 min (Fig. 2) . Peak analgesic effect was 29% above baseline current. In contrast, buprenorphine 0.4 mg caused a large and long-lived analgesic effect with a maximum increase in pain tolerance current of 23.8 (7.4) mA occurring at t=130 min. Peak analgesic effect was 160% above baseline current (P<0.01 vs 0.2 mg). The overall effect of buprenorphine on analgesia was dose-dependent over the 8 h of the study (0.2 vs 0.4 mg, P<0.01). No sex difference was observed (factors examined sex and sex-dose interaction: P>0.05).
Discussion
In the current study we examined the effect of buprenorphine 0.2 and 0.4 mg i.v. (dosed per 70 kg) on ventilation and on analgesia in healthy volunteers. We observed that doubling the dose of buprenorphine increased its peak analgesic effect by a factor of 3.5 (from 6.7 to 23.8 mA). In contrast, the timing and magnitude of respiratory depression remained unchanged by doubling the buprenorphine dose (cf. Figs 1 and 2 ). These data suggest that buprenorphine displays a plateau for respiratory depression over a dose range where no plateau in analgesic effect is observed. However, before definite conclusions can be drawn our data need to be viewed against the background of a more extensive dose-response relationship. This is important taking into account the observation, in some animal studies, of a bell-shaped (inverse U-shaped) dose-response relationship for buprenorphine's analgesic effects. 8 9 In a previous study we assessed the effect of buprenorphine 0.05, 0.1, 0. Respiratory vs analgesic effects of buprenorphine and 0.6 mg on breathing in a similar study population. 4 We observed a ceiling effect for peak respiratory depression of the drug at doses of greater than 0.1 mg. Although the design of the previous and current studies differs with respect to the duration of measurements (in contrast with the current study, we previously measured breathing continuously for 90 min) we were able to combine these two data sets on peak respiratory depression (Fig. 3) . The continuous line in Figure 3 is the data fit using a sigmoid E-max model to all data presented (including the data from the current study). The broken line is the data fit using a decaying exponential model to the complete data set. Both models give similar results, that is, that the buprenorphine 0.3 and 0.6 mg data are on the flat part of the dose-response relationship, about 50% of baseline ventilation. To the best of our knowledge, an extensive dose-response relationship of the analgesic properties of buprenorphine in human beings is not available in the literature. We recently assessed the analgesic effect of i.v. buprenorphine 0.05, 0.1 and 0.3 mg over time in 15 healthy young volunteers using our electrical pain model (A.D., unpublished observation). In Figure 4 we plotted the mean increase in current to achieve pain tolerance (relative to baseline pain tolerance current) vs dose and added the data from the current study. A dose-dependent increase in analgesic effect is observed without any sign of ceiling. We believe that this is sufficient proof to state that buprenorphine displays ceiling in respiratory depression over a dose range (0.05-0.6 mg) without causing any ceiling in analgesic effect. This is true for the applied acute pain model and the subset of subjects that we used (young and healthy volunteers using no co-medication). Finally, we cannot exclude that ceiling in analgesic effect occurs at greater doses than tested by us.
Differential effect of buprenorphine on analgesia and respiration
Our data suggest that buprenorphine is a full agonist at MOP receptors involved in pain processing but a partial agonist at MOP receptors involved in respiratory depression. Partial agonism indicates a partial effect despite full MOPreceptor occupancy. These findings are in agreement with rat data from our laboratories and with some clinical studies which show the absence of ceiling effect for analgesia (tested at much greater buprenorphine doses than tested by us) and the ability to produce 100% pain relief despite the observation of ceiling for properties other than analgesia (such as sedation and the decrease in respiratory frequency). 2 4 Buprenorphine behaves very differently from other opioids (full agonists with respect to respiratory effect and analgesia) such as morphine and fentanyl. For example, we previously measured the respiratory depressant effect of morphine simultaneously with morphine's antinociceptive effects in humans. 7 We observed that over the concentration range that caused a systematic increase in analgesia, morphine caused concentration-dependent respiratory depression without any plateau or ceiling.
It is possible that differences in receptor density may be the cause of the differential buprenorphine effect at the two typical m-opioid end-points studied by us. For example, Garrido and colleagues 10 showed in rats that progressive MOP-receptor knockdown (i.e. the reduction in MOP-binding sites) with the irreversible MOP-receptor antagonist b-funaltrexamine, caused a marked decrease in alfentanil efficacy. Alfentanil transformed from a full MOP agonist into a partial agonist at reduced MOP availability. It may then be argued that MOP density is greater at pathways in the central nervous system concerned with processing pain than at the respiratory centres in the brainstem and pons.
Another explanation for buprenorphine's behaviour may be found in a difference in the agonist/MOR/G-protein/ b-arrestin complex in pain and respiratory neurons. Opioid receptors belong to the superfamily of seventransmembrane G-protein-coupled receptors which bind to G-proteins and the regulatory protein b-arrestin upon activation. 11 Raehal and colleagues 12 showed that genetic disruption of the b-arrestin type 2 (barr2) gene (barr2 knockout mice) attenuated the respiratory depression (and acute constipation) caused by morphine. In contrast, morphine-induced antinociception was augmented in the barr2 knockout mice. 13 The authors hypothesize that barrestin may play an important G-protein independent role in signal transduction via MOP receptors that lead to respiratory depression (and gastrointestinal transit inhibition) but not via MOP receptors that lead to analgesia. G-protein independent but b-arrestin dependent activation has been observed for other receptors of the seventransmembrane receptor superfamily, such as the b 2 -adrenergic receptor.
14 Following the reasoning of Raehal and colleagues 12 and taking into account our data, this suggests that MOP-receptor activation of a G-protein independent signal transduction pathway is ligand specific: some ligands (such as fentanyl and morphine) cause changes in neuronal physiology fully dependent on G-protein activation causing full MOP-receptor responses, while others (such as buprenorphine) activate the b-arrestin protein with diminished responses. We hypothesize that signal transduction attributable to buprenorphine-activation of MOP receptors expressed on respiratory neurons is via b-arrestin mediation and not via G-protein activation. Interestingly, morphine's active metabolite morphine-6-glucuronide (M6G) displays significantly less respiratory depression than morphine (i.e. a rightward shift of the dose-response relationship). 15 A shared difference in the structure of M6G and buprenorphine with morphine is the modification of the hydroxy group at position C6 of the morphine molecule (morphine: C6-OH, buprenorphine: C6-O-CH 3 and M6G: C6-glucuronide). Possibly this modification at C6 may be the cause for reduced effect at MOP receptors expressed on respiratory neurons (cf. ref. 16 ). Further studies are needed to clarify this important issue.
In contrast with our previous study, 4 here we address the issue of buprenorphine's respiratory safety in the light of its analgesic properties. Opioid-induced respiratory depression is related to over-dosing, concurrent sedation/sleep, co-medication, the periodic nature of pain and underlying disease. The frequency of serious respiratory events related to opioid use remains poorly reported and probably poorly studied. In chronic cancer and non-cancer pain patients, respiratory complications are often erroneously taken for progression of disease and sometimes accepted-and hence unreported-in the light of the poor prognosis of the patient. However, a series of recent case-reports on fentanyl-induced severe respiratory depression and death in old and relatively healthy young patients has led to several warnings related to the use of fentanyl patches for treatment of chronic pain. [17] [18] [19] [20] The question is whether buprenorphine can make a difference, or-in other words-whether the use of buprenorphine in pain patients will cause less respiratory events than commonly used potent opioids such as morphine and fentanyl. Our data support the notion that as buprenorphine's respiratory effects are limited, buprenorphine has an advantage over other opioids such as fentanyl and morphine which do not show ceiling at a high dose but eventually cause breathing instability and apnoea. However, whether this advantage persists under specific conditions such as old age, (lung) disease and ingestion of co-medication needs further study. In opioid-addicts acute co-administration of buprenorphine and benzodiazepines is sometimes associated with fatal respiratory depression. 21 
Critique of methods
We used our pain model as a pharmacological tool and did not intend to simulate clinical (acute or chronic) pain. We had used the acute pain model (electrical transcutaneous stimulation of the skin) previously to successfully study the antinociceptive effects of morphine and M6G. 7 22 The results of these studies were comparable with clinical observations on morphine and M6G pain relief in acute and chronic pain patients with respect to analgesia and drug potency. As the healthy volunteers tested in our studies were without pain or inflammation, the term antinociception seems a more appropriate description of the opioid behaviour in the acute pain test. The choice of the term analgesia throughout this paper was taken-somewhat arbitrarily-to make a distinction from animal studies. In the current study we combined respiratory and analgesia measurements.
It may be argued that pain measurement may interfere with respiratory measurements and vice versa. This is true, pain testing may have a significant effect on breathing, often causing hyper-, hypoventilatory responses, or both, as a result of activation of behavioural respiratory drives; 23 and hypercapnia has been shown to influence pain testing. 24 We tried to minimize the complex interactive effects of pain testing and respiratory measurements by allowing ample time between measurements, but we cannot exclude some disturbing effects on both systems.
We were unable to detect significant sex differences in buprenorphine's respiratory and analgesic responses, although there was a clear trend in the data (P=0.09) with greater responses in women. Our current study was not designed to examine sex differences, such as observed earlier for morphine. 25 26 Post-hoc power analysis indicated that 20 subjects (10 men/10 women) were needed to reveal a sex difference in analgesia after buprenorphine 0.4 mg at the P=0.05 level.
In conclusion, we tested two incremental i.v. doses of buprenorphine (0.2 and 0.4 mg) on pain relief and respiratory depression in a group of healthy young volunteers. We observed that while buprenorphine's analgesic effect increased significantly, respiratory depression showed a similar magnitude and timing for the two doses tested. Taking into account additional data from our laboratory we conclude that buprenorphine displays ceiling in respiratory effect but none in analgesic effect over a dose range from 0.05 to 0.6 mg.
